Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NGM Biopharmaceuticals has partnered with Janssen Pharmaceuticals for the discovery and development of novel therapeutics against type 2 diabetes and other metabolic diseases.
Subscribe to our email newsletter
Both the companies will work together to evaluate selected protein factors identified by NGM in order to progress the development of potent candidates with glucoregulatory effects of bariatric surgery on diabetes patients.
According to the deal, Janssen will gain an exclusive worldwide license to develop, manufacture and market the resulting compounds.
NGM president and chief scientific officer Jin-Long Chen said, "We are pleased to be working with Janssen, who will bring world-class drug discovery and development expertise to the advancement of NGM’s first-in-class therapies for the treatment of patients with diabetes."
As per the transaction, Janssen will make an upfront payment, support the research of the candidates concerning the deal, make development, regulatory and commercial milestone payments in addition to sales based royalties to NGM.